A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein

BMC Microbiology

Volumn 11, Issue , 2011, Pages

  Paul, Vivek ^a,b   Rajagopalan, Sanjeev ^a   Sundarrajan, Sudarson ^a   George, Shilpa E ^a   Asrani, Jiya Y ^a   Pillai, Renjith ^a,c   Chikkamadaiah, Ravisha ^a   Durgaiah, Murali ^a   Sriram, Bharathi ^a   Padmanabhan, Sriram ^a,d  

^a Gangagen Biotechnologies Pvt Ltd   (India)

^b UNIVERSITY OF TORONTO   (Canada)

^c ALBERTA ENVIRONMENT AND PARKS   (Canada)

^d LUPIN LIMITED   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; ANTIINFECTIVE AGENT; CHIMERIC PROTEIN; CYSTEINE; GENE PRODUCT; TAIL ASSOCIATED MURALYTIC ENZYME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; CARBOXY TERMINAL SEQUENCE; GENE CONSTRUCT; HOSPITAL INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; STAPHYLOCOCCUS AUREUS; ANIMAL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS PHAGE; WISTAR RAT;

MYOVIRIDAE; POSIBACTERIA; RATTUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

AMIDOHYDROLASES; ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MYOVIRIDAE; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STAPHYLOCOCCUS PHAGES; VIRAL TAIL PROTEINS;

EID: 80053619994     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-11-226     Document Type: Article

References (48)

1. A bacteriolytic agent that detects and kills Bacillus anthracis. Schuch R, Nelson D, Fischetti VA, Nature 2002 418 884 889 10.1038/nature01026 12192412 (Pubitemid 34966308)
2. Bacteriophage lytic enzymes: novel anti-infectives. Fischetti VA, Trends Microbiol 2005 13 491 496 10.1016/j.tim.2005.08.007 16125935 (Pubitemid 41317527)
3. Bacteriophage endolysins-current state of research and applications. Loessner MJ, Curr Opin Microbiol 2005 8 480 487 10.1016/j.mib.2005.06.002 15979390 (Pubitemid 41021911)
4. Bacteriophage lysis: Mechanism and regulation. Young R, Microbiol rev 1992 56 3 430 481 1406491
5. Bacteriophage holins: Deadly diversity. Young R, J Mol Microbiol Biotechnol 2002 4 1 21 36 11763969 (Pubitemid 33121212)
6. The growth of bacteriophage and lysis of the host. Delbruck M, J Gen Physiol 1940 23 5 643 660 10.1085/jgp.23.5.643 19873180
7. The lytic enzyme of the Pseudomonas phage f6. Purification sand biochemical characterization. Caldentey J, Bamford DH, Biochim Biophys Acta 1992 1159 44 50 10.1016/0167-4838(92)90073-M 1390911
8. Role of the Gp16 lytic transglycosylase motif in bacteriophage T7 virions at the initiation of infection. Moak M, Molineux IJ, Mol Microbiol 2000 37 345 355 10.1046/j.1365-2958.2000.01995.x 10931329 (Pubitemid 30481017)
9. Bacteriophage PRD1 DNA entry uses a viral membrane-associated transglycosylase activity. Rydman PS, Bamford DH, Mol Microbiol 2000 37 356 363 10.1046/j.1365-2958.2000.01996.x 10931330 (Pubitemid 30481018)
10. Roles of Bacteriophage T4 Gene 5 and Gene s Products in Cell Lysis. Kao SH, McClain WH, J Virol 1980 34 1 104 107 6990015 (Pubitemid 10149385)
11. Isolation and characterization of the bacteriophage T4 tail-associated lysozyme. Nakagawa H, Arisaka F, Ishii S, J Virol 1985 54 460 466 3157805 (Pubitemid 15050959)
12. Peptidoglycan hydrolytic activities associated with bacteriophage virions. Moak M, Molineux IJ, Mol Microbiol 2004 51 4 1169 1183 10.1046/j.1365-2958.2003.03894.x 14763988 (Pubitemid 38270807)
13. Bacteriophage Tuc2009 encodes a tail-associated cell wall degrading activity. Kenny JG, McGrath S, Fitzgerald GF, van Sinderen DV, J Bacteriol 2004 186 3480 3491 10.1128/JB.186.11.3480-3491.2004 15150235 (Pubitemid 38661545)
14. Phage P68 virion-associated protein 17 displays activity against clinical Isolates of Staphylococcus aureus. Takac M, Blasi U, Antimicrob Agents Chemother 2005 49 2934 2940 10.1128/AAC.49.7.2934-2940.2005 15980371 (Pubitemid 40917613)
15. Tail-associated structural protein gp61 of Staphylococcus aureus phage MR11 has bifunctional lytic activity. Rashel M, Uchiyama J, Takemura I, Hoshiba H, Ujihara T, Takatsuji H, Honke K, Matsuzaki S, FEMS Microbiol Lett 2008 284 1 9 16 10.1111/j.1574-6968.2008.01152.x 18462391 (Pubitemid 351776887)
16. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR, N Engl J Med 1999 340 493 501 10.1056/ NEJM199902183400701 10021469 (Pubitemid 29093284)
17. Molecular genetics of methicillin-resistant Staphylococcus aureus. Hiramatsu K, Katayama Y, Yuzawa H, Ito T, Int J Med Microbiol 2002 292 67 74 10.1078/1438-4221-00192 12195737 (Pubitemid 34842177)
18. Staphylococcus aureus resistant to vancomycin-United States. CDC, MMWR 2002 51 565 567 12139181
19. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core surveillance (ABCs) MRSA Investigators, JAMA 2007 298 1763 71 10.1001/jama.298.15.1763 17940231 (Pubitemid 47598444)
20. The serological differentiation of staphylococcal bacteriophages. Rountree PM, J Gen Microbiol 1949 3 2 164 73 18144968
21. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. O'Flaherty S, Ross RP, Meaney W, Fitzgerald GF, Elbreki MF, Coffey A, Appl Environ Microbiol 2005 71 1836 1842 10.1128/AEM.71.4.1836-1842.2005 15812009 (Pubitemid 40546101)
22. Phage derived antimicrobial agents. Padmanabhan P, Paul VD, Saravanan RS, Sriram B, International publication Number WO2007/130655
23. Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. Baba T, Schneewind O, EMBO J 1996 15 18 4789 97 8890152 (Pubitemid 26315789)
24. A novel Bacteriophage Tail Associated Muralytic Enzyme (TAME) from PhageK and its development into a potent anti-staphylococcal chimeric protein. Paul VD, Saravanan S, Asrani J, Hebbur M, Pillai R, Sudarson S, Sukumar H, Sriram B, Padmanabhan S, In the Molecular Genetics of Bacteria and Phages Meeting, 4-9 August; Madison Wisconsin, USA
25. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Kreiswirth BN, Löfdahl S, Betley MJ, O'Reilly M, Schlievert PM, Nature 1983 305 709 12 10.1038/305709a0 6226876 (Pubitemid 13021519)
26. Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G+C content. O'Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald GF, Ross RP, J Bacteriol 2004 186 2862 2871 10.1128/JB.186.9.2862-2871.2004 15090528 (Pubitemid 38525941)
27. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs". Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ, Nucleic Acids Res 1997 25 3389 3402 10.1093/nar/25.17. 3389 9254694 (Pubitemid 27359211)
28. Pfam: clans, web tools and services. Finn RD, Mistry J, Schuster-Böckler B, Griffiths-Jones S, Hollich V, Lassmann T, Moxon S, Marshall M, Khanna A, Durbin R, Eddy SR, Sonnhammer EL, Bateman A, Nucleic Acids Research Database Issue 2006 34 247 D51
29. CDART: protein homology by domain architecture. Geer LY, Domrachev M, Lipman DJ, Bryant SH, Genome Res 2002 12 10 1619 23 10.1101/gr.278202 12368255 (Pubitemid 35175101)
30. Molecular Cloning: A Laboratory Manual. Sambrook J, Russel DW, Cold Spring Harbor Laboratory Press 2001
31. Analysis of the bacteriolytic enzymes of the autolytic Lactococcus lactis subsp. cremoris strain AM2 by renaturing polyacrylamide gel electrophoresis: identification of a prophage-encoded enzyme. Lepeuple AS, Van Gemert E, Chapot-Chartier MP, Appl Environ Microbiol 1998 64 4142 4148 9797258 (Pubitemid 28537969)
32. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. National Committee for Clinical Laboratory Standards, 1999 Approved Guideline M26- A. NCCLS, Wayne, PA
33. Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Kiser KB, Cantey-Kiser JM, Lee JC, Infect Immun 1999 67 5001 5006 10496870 (Pubitemid 29455266)
34. Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ, Antimicrob Agents Chemother 2003 47 5 1589 97 10.1128/AAC.47.5.1589-1597.2003 12709327 (Pubitemid 36548542)
35. The CHAP domain: a large family of amidases including GSP amidase and peptidoglycan hydrolases. Bateman A, Rawlings ND, Trends Biochem Sci 2003 5 234 237 (Pubitemid 36588664)
36. Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. Donovan DM, Lardeo M, Foster-Frey J, FEMS Microbiol Lett 2006 265 1 133 9 10.1111/j.1574-6968.2006.00483.x 17054440 (Pubitemid 44715454)
37. Characterization of a bacteriophage related to R-type pyocins. Kageyama M, Shinomiya T, Aihara Y, Kobayashi M, J Virol 1979 32 951 957 117120 (Pubitemid 10168485)
38. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Nakayama K, Takashima K, Ishihara H, Shinomiya T, Kageyama M, Kanaya S, Ohnishi M, Murata T, Mori H, Hayashi T, Mol Microbiol 2000 38 2 213 31 10.1046/j.1365-2958.2000.02135.x 11069649
39. Bactericidal activity of the tail of Pseudomonas aeruginosa bacteriophage PS17. Shinomiya T, Shiga S, J Virol 1979 32 3 958 967 117121 (Pubitemid 10168486)
40. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Pritchard DG, Dong S, Barker JR, Engler JA, Microbiology 2004 150 2079 2087 10.1099/mic.0.27063-0 15256551 (Pubitemid 39117622)
41. Control mechanisms in dsDNA bacteriophage assembly: The Bacteriophages. Casjens S, Hendrix R, Kluwer Academic/Plenum Publishers, Calendar R, 1988 15 91
42. Bacteriophage endolysins-current state of research and applications. Loessner MJ, Curr Opin Microbiol 2005 8 4 480 7 10.1016/j.mib.2005.06.002 15979390 (Pubitemid 41021911)
43. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Kluytmans J, van Belkum A, Verbrugh H, Clin Microbiol Rev 1997 10 3 505 20 9227864 (Pubitemid 27359263)
44. Nasal Carriage as a Source of Staphylococcus Aureus Bacteremia Study Group. von Eiff C, Becker K, Machka K, Stammer H, Peters G, N Engl J Med 2001 344 11 6 10.1056/NEJM200101043440102 11136954 (Pubitemid 32064839)
45. Evolutionary analyses of Staphylococcus aureus identify genetic relationships between nasal carriage and clinical isolates. Lamers RP, Stinnett JW, Muthukrishnan G, Parkinson CL, Cole AM, PLoS One 2011 21; 6 1 16426 21998748
46. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. van Rijen M, Bonten M, Wenzel R, Kluytmans J, Cochrane Database Syst Rev 2008 8 4 D006216
47. Mupirocin Resistance Related to Increasing Mupirocin Use in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus in a Pediatric Population. Hogue JS, Buttke P, Braun LE, Fairchok MP, J Clin Microbiol 2010 48 7 2599 2600 10.1128/JCM.02118-09 20421433
48. High Frequencies of Clindamycin and Tetracycline Resistance in Methicillin-Resistant Staphylococcus aureus Pulsed-Field Type USA300 Isolates Collected at a Boston Ambulatory Health Center. Han LL, McDougal LK, Gorwitz RJ, Mayer KH, Patel JB, Sennott JM, Fontana JL, J Clin Microbiol 2007 45 1350 2 10.1128/JCM.02274-06 17287335 (Pubitemid 46626515)